Evaluation of Malignancy Risk in Scleroderma by Antibody Profile.

Evaluation of Malignancy Risk in Scleroderma by Antibody Profile. Br J Dermatol. 2020 Sep 13;: Authors: Lertphanichkul C, Smith GP Abstract An increased risk of malignancy in systemic sclerosis (SSc) has been reported.1 Moreover, a close temporal relationship between onset of SSc and malignancy has been reported in patients with anti-RNA polymerase III antibody.2 We conducted this study to add to the available data on types and rates of malignancy and to evaluate if our SSc population showed an association between cancer and SSc onset and whether this risk was different in different SSc-specific autoantibody groups. PMID: 32920853 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32920853?dopt=Abstract

Source: The British Journal of Dermatology - September 12, 2020 Category: Dermatology Authors: Lertphanichkul C, Smith GP Tags: Br J Dermatol Source Type: research